

THE IRWIN D. MANDEL

Advances in Cardiovascular Risk Reduction

IMPROVING TREATMENT FOR PATIENTS WITH DIABETES

Thursday, May 9, 2019

New York, NY

nyulmc.org/cvriskcme

Jointly provided by NYU School of Medicine and the
New York State Chapter American College of Physicians (NYACP)



New York State
CHAPTER



SPEAKERS

COURSE DIRECTOR

Arthur Z. Schwartzbard, MD

Associate Professor of Medicine
Director, Clinical Lipid Research
Director, Preventive Cardiology
Fellowship Program
Center for the Prevention of
Cardiovascular Disease
NYU School of Medicine

COURSE PLANNERS

Jeffrey S. Berger, MD

Edward A. Fisher, MD, PhD, MPH

Mattia Gilmartin, RN, PhD, FAAN

Ira J. Goldberg, MD

Ana M. Mola, RN, PhD, ANP-BC, MAACVPR

Lawrence Phillips, MD

NY Chapter American
College of Physicians

James A. Underberg, MD

NYU LANGONE HEALTH SPEAKERS

Jeffrey S. Berger, MD

Associate Professor of
Medicine and Surgery
Director, Cardiovascular
Thrombosis Program
Co-Director, Center for the Prevention
of Cardiovascular Disease

Edward A. Fisher, MD, PhD, MPH

Leon H. Charney Professor of
Cardiovascular Medicine
Professor of Cell Biology, Medicine,
Microbiology, and Pediatrics
Director, Marc and Ruti Bell
Vascular Biology Program
Co-Director, Center for the Prevention
of Cardiovascular Disease

Lauren H. Golden, MD

Clinical Associate
Professor of Medicine
Director, Center for Diabetes
and Metabolic Health

Ira J. Goldberg, MD

Clarissa and Edgar Bronfman, Jr.
Professor of Endocrinology
Director, Division of Endocrinology,
Diabetes and Metabolism

Dennis A. Goodman, MD

Clinical Professor of Medicine
Director, Integrative Medicine

Sean P. Heffron, MD, MSc

Assistant Professor of Medicine

Ana M. Mola, RN, PhD, ANP-BC, MAACVPR

Clinical Assistant Professor of
Rehabilitation Medicine
Director, Care Transitions and
Population Health Management

Jonathan Newman, MD, MPH

Eugene Braunwald, MD
Assistant Professor of Cardiology

James A. Underberg, MD

Clinical Assistant Professor
of Medicine

Howard Weintraub, MD

Clinical Professor of Medicine
Clinical Director, Center for the
Prevention of Cardiovascular Disease
Associate Director, Preventive
Cardiology Fellowship Program

GUEST SPEAKERS

Paul Ridker, MD

Eugene Braunwald
Professor of Medicine
Harvard Medical School
Senior Physician
Brigham and Women's Hospital
Boston, MA

Clay F. Semenkovich, MD

Irene E. and Michael M. Karl Professor
Chief, Division of Endocrinology,
Metabolism and Lipid Research
Professor of Medicine and of
Cell Biology and Physiology
Washington University in St. Louis
School of Medicine
St. Louis, MO

Kenneth Walsh, PhD

Lockhart B. McGuire Professor
of Internal Medicine
University of Virginia
Charlottesville, VA



The Irwin D. Mandel Advances in Cardiovascular Risk Reduction

COURSE DESCRIPTION

This one-day course will cover state-of-the-art management of patients with cardiovascular risk factors, with a focus on prevention. The morning session will highlight the latest scientific and clinical advances in the management of diabetes with topics to include insulin resistance, new approaches to control type 1 and type 2 and side effects of new diabetes drugs. The course will review the challenges of treating statin intolerant patients, best practices in primary prevention and review the inflammation hypothesis, and anti-inflammatory therapies for atherosclerosis. A presentation on clonal hematopoiesis will include new research on this recently identified age-related disorder. A presentation on rheumatological diseases will highlight cardiovascular risk prevention strategies to manage patients with these inflammatory medical conditions. The course will provide an in-depth look at the latest scientific studies examining the atheroprotective properties of HDL on atherosclerotic risk. This year, the featured research-oriented presentation will focus on diabetes with a presentation on the role of vascular lipid metabolism in the vascular complications in the diabetic patient.

EDUCATIONAL OBJECTIVES

After participating in this activity, clinicians should be able to:

- Describe the role of vascular lipid metabolism in the vascular complications in the diabetic patient
- Describe the burden of insulin resistance, scientific advances in understanding insulin pathways, and clinical approaches to prevent the onset of T2DM in patients with insulin resistance
- Summarize the benefits and possible disadvantages to new pharmacological agents for diabetes and how to personalize treatments and maximize benefits for patients with cardiovascular co-morbidities
- Summarize the side effects of GLP1 receptor agonists and SGLT2 inhibitors that may impact non adherence and result in adverse clinical outcomes
- Discuss the impact of statin intolerance on cardiovascular risk reduction and outline strategies to manage statin intolerant patients
- Summarize the data relevant to the impact of treatment of hypertension, lipid lowering, as well as dietary change
- Describe how the landmark CANTOS trial provided the first clinical proof confirming the inflammatory hypothesis of atherothrombosis
- Describe how clonal hematopoiesis correlates with an increased risk of atherosclerotic cardiovascular disease

- Describe the increased cardiovascular risk in patients with rheumatological diseases, pathogenesis for these findings, and ways to improve patient outcomes
- Summarize the evidence for HDL in atherosclerotic regression and describe how HDL alters the inflammation of atherosclerotic plaques

TARGET AUDIENCE

Cardiologists, endocrinologists, lipidologists, internists, general practice, family practitioners, advanced practice providers, nurses, and physician trainees with an interest in the prevention of heart disease

Co-Organized by the Division of Cardiology and the Division of Endocrinology, Diabetes and Metabolism

LOCATION

NYU Langone Health
Alumni Hall
550 First Avenue
New York, NY 10016

COURSE FEES

Full: \$175

Reduced*: \$95

Residents and Fellows: \$60

* Reduced fee applies to all nursing and allied health care professionals, as well as NYU Langone Health Faculty and Staff

Please note: This course is eligible for NYU School of Medicine Alumni discount.

REGISTRATION

nyulmc.org/cvriskcme

After 12 pm on May 7, 2019, only onsite registration is available, provided the course has not reached capacity. Onsite registrants will incur an additional \$20 charge. Registration is non-transferable.

ELECTRONIC SYLLABUS

Course syllabus will only be distributed electronically. A link will be sent the week of the course where you can view, download or print course information and presentations in advance. This link will also allow you to view the course syllabus on your smartphone, tablet, or laptop during the course. Course presentations remain available for one year after the course.

REFUND POLICY

Submit your request for a refund of course fees more than \$75 no later than 7 days before the course start date. No refunds will be issued for cancellations or no-shows after that time. To request a refund, email cme@nyulangone.org. A \$75 administrative fee will be deducted.

COURSE CANCELLATION POLICY

If a course is cancelled due to inclement weather, insufficient enrollment, or any other reason, NYU SOM will refund registration fees in full. NYU SOM will provide at least two weeks' advance notice if cancelling due to insufficient enrollment and as soon as possible in all other circumstances. NYU SOM is not responsible for any airfare, hotel, or other non-cancellable costs incurred by the registrant.

CONTACT INFORMATION

NYU School of Medicine
Phone: 212-263-5295
Fax: 212-263-5293
Email: cme@nyulangone.org

CME ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the NYU School of Medicine and New York State Chapter American College of Physicians. The NYU School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

The NYU School of Medicine designates this live activity for a maximum of 7.50 *AMA PRA Category 1 Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTINUING NURSING EDUCATION CONTACT HOURS

This program will award 7.50 continuing nursing education contact hours. Participants must complete a course evaluation to claim contact hours for this learning activity.

The NYU Meyers College of Nursing Center for Continuing Education in Nursing is accredited as a provider of continuing nursing education by the American Nurses' Credentialing Center's Commission on Accreditation.

PROVIDED BY

Jointly provided by NYU School of Medicine and the New York State Chapter American College of Physicians (NYACP)

NYU Langone's Center for the Prevention of Cardiovascular Disease is a component of the Leon H. Charney Division of Cardiology. To learn more about our Center and programs visit nyulangone.org/cvdprevention



AGENDA | Thursday, May 9, 2019

- 7:45 am Registration and Continental Breakfast**
- 8:20 Course Director Welcome**
Arthur Z. Schwartzbard, MD
- 8:30 Vascular Lipid Metabolism and Chronic Disease**
Clay F. Semenkovich, MD
- 9:00 Insulin Resistance**
Ira J. Goldberg, MD
- 9:30 New Approaches to Control Type 1 and Type 2 Diabetes**
Lauren H. Golden, MD
- 10:00 Coffee Break**
- 10:15 Side Effects of New Diabetes Drugs**
Jonathan Newman, MD, MPH
- 10:45 8th Annual Leon H. Charney Lecture**
Statin Intolerance: Real vs. Perceived: Does it Matter?
James A. Underberg, MD
Dr. James Underberg's presentation has been designated as the 8th Annual Leon H. Charney Lecture. This lecture series features outstanding basic, translational or clinical research by a NYU Langone faculty member in an area related to the prevention of cardiovascular disease.
- 11:15 Morning Panel**
Course faculty and panel members:
Dennis A. Goodman, MD
Sean P. Heffron, MD, MSc
Ana M. Mola, RN, PhD, ANP-BC, MAACVPR
- 12:00 pm Lunch and Case Conference**
Ira J. Goldberg, MD
- 1:00 Primary Prevention**
Howard Weintraub, MD
- 1:30 Inflammation Therapies**
Paul Ridker, MD
- 2:00 Clonal Hematopoiesis and Atherosclerosis**
Kenneth Walsh, PhD
- 2:30 Coffee Break**
- 2:45 Cardiovascular Risk in Patients with Rheumatological Diseases**
Jeffrey S. Berger, MD
- 3:15 HDL and Atherosclerosis: Still Relevant?**
Edward A. Fisher, MD, PhD, MPH
- 3:45 Afternoon Panel Discussion**
Course faculty and Panel Members
- 4:30 pm Adjourn**



THE IRWIN D. MANDEL

Advances in Cardiovascular Risk Reduction

IMPROVING TREATMENT
FOR PATIENTS WITH DIABETES

May 9, 2019

nyulmc.org/cvriskcme



NYU School of Medicine
550 First Avenue, MS1195
New York, NY 10016

Non-Profit Org.
U.S. Postage
PAID
New York, NY
Permit #8167